tiprankstipranks
Advertisement
Advertisement

Kiromic BioPharma reports interim results from Deltacel-01 trial

Kiromic BioPharma reported interim results near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel, the company’s allogeneic, off-the-shelf, Gamma Delta T-cell, or GDT, therapy, in patients with stage 4 metastatic non-small cell lung cancer, or NSCLC, who have failed to respond to standard therapies. Based on data from the five patients evaluated for Progression-Free Survival, or PFS, in the long-term follow-up, Kiromic has registered a PFS ranging from 2 to 8 months, with an average of 4.8 months. No dose limiting toxicities have been reported by the clinical site for patients that have completed the full course of therapy. One patient was withdrawn from the study before completing the full course of therapy due to an adverse event related to a pre-existing co-morbidity and unrelated to Deltacel. Consequently, this subject could not be evaluated for PFS. Additionally, the sixth and last patient in Part 1 of the Deltacel-01 study started treatment on August 6. Kiromic expects to obtain early safety and tolerability outcomes from the last enrolled patient in September and efficacy results in early October. Kiromic is on track to initiate Part 2 of Deltacel-01 in September.

Claim 30% Off TipRanks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1